Blinatumomab, a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL).
| I N TR ODU C TI ON
B-ALL blasts. 3 In a pivotal, multicenter, phase 2 trial of blinatumomab, the rate of complete remission (CR) and CR with partial hematologic recovery (CRi) was 43%, and the median overall survival (OS) was 6.1 months. 4 These findings were confirmed in a randomized phase III trial in which blinatumomab resulted in an overall response rate of 44% and a median survival of 7.7 months in patients with R/R B-cell ALL, which was significantly superior to standard-of-care chemotherapy. 5 Despite this improvement, most patients lose their response over time. 4, 5 Understanding the outcome after blinatumomab treatment and the changes in CD19 expression levels on B-ALL blasts is important for identifying patients who might benefit from specific strategies, such as allogeneic stem cell transplantation (ASCT), subsequent CAR T-cell therapies, or other investigational agents. The aim of this analysis is to summarize the outcome of patients with R/R B-ALL after blinatumomab failure.
| P A TI EN TS A N D M ETH OD S
We reviewed 84 patients with R/R B-cell ALL treated with blinatumo- Detailed eligibility criteria and treatment schema were previously reported. 4, 5 Immunophenotyping was performed by multiparameter flow cytometry in all patients. 6 Minimal residual disease (MRD) assessment were performed using multiparameter flow cytometry (for patients treated at MD Anderson Cancer Center) and polymerase chain reaction (PCR) analysis (for patients treated at Universitätsklini-kum W€ urzburg) as described previously. [6] [7] [8] Of the 84 patients treated with blinatumomab, 15 who responded, underwent ASCT and remained in CR at last follow-up, and one who remained in CR without ASCT were excluded. Sixty-eight patients were either refractory (n 5 38) or lost their response (n 5 30) and were evaluable for the analysis.
| RE S U L TS
The clinical characteristics of the 68 patients with blinatumomab failure are summarized in Table 1 Loss of CD19 expression was associated with failure of blinatumomab and CAR T-cell therapies in 30% and 60% of the cases, respectively. [11] [12] [13] [14] The mechanisms underlying the loss of CD19 expression are insufficiently understood. Braig and colleagues described four patients with B-cell ALL who developed CD19-negative relapse after treatment with blinatumomab. 15 All four cases showed an immunophenotype identical to the primary diagnosis except for the loss of CD19 expression, arguing in favor of an isolated molecular event. In patients treated with CART-19, genetic alterations and alternatively spliced, truncated CD19 variants have been described to account for resistance. 16 In addition, a myeloid lineage shift has been shown to drive resistance in patients with KMT2A (previously MLL) ALL on blinatumomab and CAR T-cell therapy. 17, 18 Ruella and colleagues have recently demonstrated the existence in B-ALL of rare CD19-negative malignant cells expressing CD123 at baseline; they showed that these cells can be responsible for relapse due to potent selective pressure by CART19
and CD19-negative subclone emergence. 19 In our series, only five patients (8%) had ALL recurrence with CD19-negative blasts; while 56 
